Regulation of sympathetic tone and arterial pressure by rostral ventrolateral medulla after depletion of C1 cells in rat.
1. In this study we examined whether the rostral ventrolateral medulla (RVLM) maintains resting sympathetic vasomotor tone and activates sympathetic nerve activity (SNA) after the depletion of bulbospinal C1 adrenergic neurones. 2. Bulbospinal C1 cells were destroyed ( approximately 84% loss) by bilateral microinjections (spinal segments T2-T3) of an anti-dopamine-beta-hydroxylase antibody conjugated to the ribosomal toxin saporin (anti-DH-SAP). 3. Extracellular recording and juxtacellular labelling of bulbospinal barosensitive neurones in the RVLM revealed that treatment with anti-DH-SAP spared the lightly myelinated neurones with no tyrosine hydroxylase immunoreactivity. 4. In rats treated with anti-DH-SAP, inhibition of RVLM neurones by bilateral microinjection of muscimol eliminated splanchnic SNA and produced the same degree of hypotension as in control rats. 5. Following treatment with anti-DH-SAP the sympathoexcitatory (splanchnic nerve) and pressor responses to electrical stimulation of the RVLM were reduced. 6. Treatment with anti-DH-SAP also eliminated the majority of A5 noradrenergic neurones. However, rats with selective lesion of A5 cells by microinjection of 6-hydroxydopamine into the pons showed no deficits to stimulation of the RVLM. 7. In summary, the loss of 84% of bulbospinal adrenergic neurones does not alter the ability of RVLM to maintain SNA and arterial pressure at rest in anaesthetized rats, but this loss reduces the sympathoexcitatory and pressor responses evoked by RVLM stimulation. The data suggest sympathoexcitatory roles for both the C1 cells and non-C1 cells of the RVLM and further suggest the C1 cells are critical for the full expression of sympathoexcitatory responses generated by the RVLM.
Schreihofer
A M
AM
Department of Pharmacology, University of Virginia, Charlottesville, VA 22908-0735, USA.
Stornetta
R L
RL
Guyenet
P G
PG
D000818:Animals; D001794:Blood Pressure / Q000502:physiology*; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors; D004558:Electric Stimulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018755:GABA Agonists / Q000008:administration & dosage / Q000494:pharmacology; D006624:Hippocampus / Q000166:cytology / Q000502:physiology*; D007150:Immunohistochemistry; D000922:Immunotoxins; D008297:Male; D008526:Medulla Oblongata / Q000502:physiology*; D008845:Microinjections; D009118:Muscimol / Q000008:administration & dosage / Q000494:pharmacology; D009699:N-Glycosyl Hydrolases; D009474:Neurons / Q000502:physiology*; D010940:Plant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins; D013127:Spinal Nerves / Q000502:physiology; D013563:Sympathectomy, Chemical; D013564:Sympathetic Nervous System / Q000166:cytology / Q000502:physiology*
D004791:Enzyme Inhibitors; D018755:GABA Agonists; D000922:Immunotoxins; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D009118:Muscimol; D004299:Dopamine beta-Hydroxylase; D009699:N-Glycosyl Hydrolases; D000076985:Saporins